The FDA has classified a recall of tadalafil USP — the bulk active ingredient, supplied in 500 g bags labelled "For Prescription Compounding Only" by Shoolin Pharma Chem LLP — as Class II, following deviations from current good manufacturing practice noted during an FDA inspection. The recall status is recorded as ongoing.
This is not a recall of a licensed tablet. It is a recall of starting material sold to compounding pharmacies, and a Class II classification means use may cause temporary or medically reversible harm with remote probability of serious injury. No adverse event has been attributed to it, and the finding is a process deviation at the manufacturing site.
The reason it matters in a urology clinic is the route by which tadalafil reaches patients outside your prescription. Compounded phosphodiesterase-5 inhibitors, and the far larger grey market of unlicensed 'performance' preparations, are drawn from bulk API of exactly this kind, and a CGMP deviation in the supply chain is precisely the mechanism by which content and purity go wrong. Most men taking tadalafil have not been asked where theirs came from. Add the question. A licensed tablet from a pharmacy is a different product from a compounded troche or a sachet bought online, whatever the label says, and the dose in the latter is not something the prescriber or the patient can verify.
- Ask every man on a PDE5 inhibitor where he obtains it, not only what he takes.
- Distinguish a licensed finished product from a compounded preparation when recording the drug history.
- Warn against unlicensed online sources — nitrate co-ingestion risk is the same whatever the provenance.
- Report suspected substandard product through the national pharmacovigilance route rather than assuming somebody else has.
- Do not tell a patient on a licensed tablet that his medicine has been recalled; this one has not.
Why it matters
The drug history most men give is incomplete in exactly the direction this recall touches.
Don't overread it
This is a manufacturing deviation in bulk ingredient, not a safety finding about tadalafil itself.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free